先天性副腎過形成治療の世界市場 (2025年～2033年)

先天性副腎過形成治療の世界市場は、2024年に2億5,000万米ドルに達し、2033年には4億1,000万米ドルに達すると予測され、予測期間2025年～2033年のCAGRは6.6％で成長する見込みです。

先天性副腎過形成症（CAH）は、副腎ホルモン合成に不可欠な酵素を産生する遺伝子の変異によって引き起こされる常染色体劣性疾患です。CAH患者では、コルチゾールの産生ができないため、視床下部-下垂体-副腎（HPA）軸の正常なフィードバックループが破綻します。このため、副腎皮質刺激ホルモン（ACTH）の過剰分泌、副腎過形成、および副腎アンドロゲン濃度の上昇が起こります。

その結果、CAH患者は、思春期早発症、生殖能障害、多毛症、ざ瘡、副腎皮質腫瘍、および生活の質の低下を経験します。女性患者はまた、男性化した生殖器や月経不順を経験することもあります。現在、アンドロゲン過剰産生を抑制する唯一の治療法は、超高用量のグルココルチコイドを投与することです。しかし、長期にわたるGC療法には、糖尿病、心血管疾患、発育不全、骨粗鬆症、皮膚の菲薄化、胃腸合併症、寿命の短縮などの重大なリスクが伴います。

市場力学：

促進要因と抑制要因

研究開発への投資

研究開発への投資は世界の先天性副腎過形成治療市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。先天性副腎過形成（CAH）治療市場は、クリネカーフォント、SPR001、クロノコート、AAV BBP-631のような革新的な治療法の導入により、医学研究が顕著に進展しています。これらの開発は、グルココルチコイドやミネラルコルチコイドへの依存を緩和しながら治療効果を高めることを目的としており、従来の治療アプローチに伴う治療上のギャップや長期的な合併症の両方に対処しています。

研究開発（R&D）は、世界の先天性副腎過形成（CAH）治療市場の成長と進化にとって極めて重要です。研究開発への多額の投資は、遺伝子治療、ACTH受容体拮抗薬、その他の標的治療など、従来のグルココルチコイド療法を超える新たな治療選択肢の創出に役立っています。これらの進歩は、CAHの症状を管理するだけでなく、根本的な原因に対処することを目的としており、より効果的で長期的な解決策となる可能性があります。

研究開発資金により、CAHの遺伝的・生化学的メカニズムに関するより深い研究が可能になります。これらのプロセスをより深く理解することで、より正確に病気を治療し、現在の治療に伴う副作用を軽減する治療法の開発につながる可能性があります。研究開発投資による継続的な臨床試験は、FDAのような規制機関からの新薬承認につながっており、市場における新規治療の機会を広げています。

さらに、業界の主要企業は、この先天性副腎過形成治療市場の成長を促進する研究開発に力を入れています。例えば、2024年12月、Spruce Biosciences, Inc.は、先天性副腎過形成（CAH）の成人を対象としたチルダセルフォンのCAHmelia-204試験と、成人および小児のCAH患者を対象としたCAHptain-205試験のトップライン結果を報告しました。

また、クリネティクス・ファーマシューティカルズ・インクは2024年6月、2番目の臨床候補である1日1回経口投与の副腎皮質刺激ホルモン（ACTH）受容体拮抗薬アトゥメルナント（CRN04894）の開発プログラムから得られた最初の知見を発表しました。内分泌学会年次総会（ENDO2024）で発表されたこの成果には、米国国立衛生研究所（NIH）と共同で実施したACTH依存性クッシング症候群（ADCS）患者を対象としたフェーズ1b/2a非盲検試験の予備的データが含まれています。これらすべての要因が、世界の先天性副腎過形成治療市場に需要をもたらしています。

さらに、新興の非ステロイド系治療薬に対する需要の高まりも、先天性副腎過形成治療の世界市場拡大に寄与しています。

高い治療費

治療費の高さが先天性副腎過形成治療の世界市場の成長を阻害する可能性があります。先天性副腎過形成（CAH）、特に県警的な病型の治療には、グルココルチコイド（GC）療法とミネラルコルチコイドによる生涯にわたる管理が必要となることが多く、いずれも高額となる可能性があります。

さらに、頻繁なモニタリングと患者の病状の変化に基づく投与量の調整が、ヘルスケアコストをさらに増加させます。高額の直接医療費は、生産性の低下、医療機関への受診の増加、関連合併症（骨粗鬆症、糖尿病、心血管疾患など）の長期管理といった間接的なコストによってさらに重くなり、これらすべてが全体的な経済的負担の一因となっています。

目次

第1章 分析手法と分析範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 研究開発への投資
    • 治療選択肢の進歩
  • 抑制要因
    • 治療費の高騰
    • 認識と診断の限界
  • 機会
    • 新たな非ステロイド療法
  • 影響分析

第5章 戦略的洞察と業界展望

• 市場のリーダーと先駆者
• 新たな先駆者と主要企業
• 最大の売上を誇るブランドを確立したリーダー
• 確立された製品を持つ市場リーダー
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の研究
• 規制と償還の情勢
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析：ベストケース・ベースケース・ワーストケースの予測
• 価格分析と価格市場力学
• キーオピニオンリーダー (KOL)

第6章 種類別

• 典型的先天性副腎過形成
• 非典型的先天性副腎過形成

第7章 薬剤の種類別

• コルチコステロイド
  • ヒドロコルチゾン
  • プレドニゾン
  • デキサメタゾン
  • フルドロコルチゾン
• クリネサーフォント
• スピロノラクトン
• その他

第8章 投与経路別

• 経口
• 注入

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Neurocrine Biosciences, Inc.
  • 企業概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 製品販売の実績・予測
    • 製品販売量
  • 財務概要
    • 企業の収益
    • 収益シェア：地域別
    • 収益予測
  • 主な動向
    • 企業合併・買収 (M&A)
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• AdvaCare Pharma
• Teva Pharmaceuticals USA, Inc.
• Sandoz
• THE SEARLE COMPANY LTD.
• Spruce Biosciences, Inc.
• Crinetics Pharmaceuticals, Inc.
• BridgeBio Inc.
• H. Lundbeck A/S

第13章 付録

The global congenital adrenal hyperplasia treatment market reached US$ 0.25 billion in 2024 and is expected to reach US$ 0.41 billion by 2033, growing at a CAGR of 6.6% during the forecast period 2025-2033.

Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder caused by a mutation in the gene responsible for producing an enzyme essential for adrenal hormone synthesis. In individuals with CAH, the inability to produce cortisol disrupts the normal feedback loop of the hypothalamic-pituitary-adrenal (HPA) axis. This leads to excessive secretion of adrenocorticotropic hormone (ACTH), adrenal gland hyperplasia, and elevated adrenal androgen levels.

As a result, CAH patients may experience premature puberty, impaired fertility, hirsutism, acne, adrenal rest tumors, and a reduced quality of life. Female patients may also develop virilized genitalia and experience menstrual irregularities. Currently, the only available treatment to suppress excess androgen production involves administering supraphysiologic doses of glucocorticoids. However, long-term GC therapy carries significant risks, including diabetes, cardiovascular disease, stunted growth, osteoporosis, skin thinning, gastrointestinal complications, and a reduced lifespan.

Market Dynamics: Drivers & Restraints

Investments in Research and Development

The investments in research and development are significantly driving the growth of the global congenital adrenal hyperplasia treatment market and are expected to drive throughout the market forecast period. The congenital adrenal hyperplasia (CAH) treatment market is experiencing notable progress in medical research, with the introduction of innovative therapies like Crinecerfont, SPR001, Chronocort, and AAV BBP-631. These developments aim to enhance treatment effectiveness while alleviating the dependency on glucocorticoids and mineralocorticoids, addressing both therapeutic gaps and long-term complications associated with traditional treatment approaches.

Research and development (R&D) are pivotal to the growth and evolution of the global congenital adrenal hyperplasia (CAH) treatment market. Significant R&D investments are helping to create new treatment options beyond traditional glucocorticoid therapy, such as gene therapies, ACTH receptor antagonists, and other targeted therapies. These advancements aim to address the root cause of CAH rather than just managing symptoms, offering the potential for more effective and long-term solutions.

R&D funding allows for deeper research into the genetic and biochemical mechanisms of CAH. A better understanding of these processes can lead to the development of therapies that more precisely target the disease, reducing side effects associated with current treatments. Ongoing clinical trials funded by R&D investments are leading to new drug approvals from regulatory bodies like the FDA, which is opening up opportunities for novel treatments in the market.

Additionally, key players in the industry are more focused on the research and developments that would drive this congenital adrenal hyperplasia treatment market growth. For instance, in December 2024, Spruce Biosciences, Inc. reported topline results from its CAHmelia-204 study of tildacerfont in adults with congenital adrenal hyperplasia (CAH) and its CAHptain-205 study in both adult and pediatric CAH patients.

Also, in June 2024, Crinetics Pharmaceuticals, Inc. announced initial findings from the development program of its second clinical candidate, atumelnant (CRN04894), a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist. The results, presented at the Endocrine Society's annual meeting (ENDO2024), include preliminary data from a Phase 1b/2a open-label study in patients with ACTH-dependent Cushing's syndrome (ADCS) conducted in collaboration with the National Institutes of Health (NIH). All these factors demand the global congenital adrenal hyperplasia treatment market.

Moreover, the rising demand for emerging non-steroidal therapies contributes to the global congenital adrenal hyperplasia treatment market expansion.

High Cost of Treatment

The high cost of treatment may hinder the growth of the global congenital adrenal hyperplasia treatment market. The treatment of congenital adrenal hyperplasia (CAH), particularly the classic form of the disease, often involves lifelong management with glucocorticoid (GC) therapy and mineralocorticoids, both of which can be expensive.

Additionally, frequent monitoring and adjustments in doses based on changes in the patient's condition further increase healthcare costs. The high direct costs of medical care are compounded by indirect costs, such as reduced productivity, increased healthcare visits, and long-term management of related complications (e.g., osteoporosis, diabetes, cardiovascular diseases), all of which contribute to the overall financial burden.

Segment Analysis

The global congenital adrenal hyperplasia treatment market is segmented based on type, drug type, route of administration, distribution channel, and region.

Drug Type:

The hydrocortisone in the drug type segment is expected to dominate with the highest market share.

Hydrocortisone plays a central role in the treatment of congenital adrenal hyperplasia (CAH), a rare genetic disorder that affects the adrenal glands. The global CAH treatment market is primarily segmented by the types of therapies used, including traditional glucocorticoids like hydrocortisone, newer biologics, and emerging therapies. Hydrocortisone remains one of the most commonly used treatments for CAH, specifically in its modified-release form, which helps replicate the natural circadian rhythm of cortisol production.

The conventional formulation of hydrocortisone is commonly used in CAH patients to manage adrenal insufficiency and prevent adrenal crisis. However, it requires multiple daily doses, which can be challenging for patients. Modified formulations, such as Chronocort (developed by Diurnal Ltd.), are designed to mimic natural cortisol secretion and require fewer doses per day. These formulations help reduce the frequency of administration, improve treatment adherence, and offer more physiological cortisol levels throughout the day.

Hydrocortisone is often used in combination with other therapies, such as fludrocortisone, to manage electrolyte imbalances in CAH patients. It may also be combined with emerging treatments like ACTH receptor antagonists or gene therapies to provide more comprehensive management.

Geographical Analysis

North America is expected to hold a significant position in the global congenital adrenal hyperplasia treatment market.

North America holds a substantial position in the global congenital adrenal hyperplasia treatment market and is expected to hold most of the market share in the forecast period. The key factors contributing to the region's dominance include advancements in medical care, the availability of new therapies, and high healthcare access.

Additionally, in this region, a major number of key players are present, with well-advanced healthcare infrastructure, product launches, approvals, and a rising number of clinical trials. For instance, in December 2024, the U.S. Food and Drug Administration (FDA) approved crinecerfont (Crenessity) as a treatment for classic congenital adrenal hyperplasia (CAH). This marks the first new therapeutic option in 70 years for both adults and children aged 4 and older affected by this rare, lifelong condition.

Also, in May 2024, Neurocrine Biosciences, Inc. presented baseline data from the CAHtalyst Phase 3 studies of crinecerfont in both adult and pediatric patients with congenital adrenal hyperplasia (CAH). Additionally, they shared data from a Phase 2 clinical study (CHAMPAIN) involving modified-release hydrocortisone (Chronocort) in participants with primary adrenal insufficiency, as well as results from a Phase 3 extension study in CAH patients. Thus, the above factors are consolidating the region's position as a dominant force in the global congenital adrenal hyperplasia treatment market.

Asia Pacific is growing at the fastest pace in the global congenital adrenal hyperplasia treatment market share

Asia Pacific holds the fastest pace in the global congenital adrenal hyperplasia treatment market and is expected to hold most of the market share. The prevalence of CAH in the Asia-Pacific is higher than in other regions, particularly among certain populations, which increases the demand for targeted treatments. Countries with large populations, such as India and China, are seeing rising numbers of CAH cases, further expanding the patient pool and the need for effective treatments.

Awareness of CAH is steadily growing across the Asia-Pacific region, especially as more healthcare providers are recognizing the importance of early diagnosis through newborn screening programs. This has led to earlier identification and treatment of the disease, helping to improve patient outcomes and driving demand for treatment options. Countries like Japan, South Korea, and Australia have made strides in genetic testing and screening programs, leading to better detection rates of CAH, which in turn boosts the market for CAH treatments.

Developed countries like Japan, Australia, and South Korea have advanced healthcare systems with widespread access to specialty care. These regions have well-established healthcare networks and often have access to cutting-edge treatments such as modified-release hydrocortisone and newer biologics. In emerging markets like India and China, improvements in healthcare infrastructure and access to modern medical facilities have made it easier for patients to receive timely diagnosis and treatment, fostering market growth.

Emerging therapies, such as modified-release hydrocortisone, gene therapies, and ACTH receptor antagonists, are gaining traction in the Asia-Pacific market. As global pharmaceutical companies continue to expand their reach in this region, more innovative treatments are becoming available to patients with CAH.

Additionally, key players' strategies, such as partnerships and collaborations, would drive this global congenital adrenal hyperplasia treatment market growth. For instance, in January 2023, Spruce Biosciences and Kaken Pharmaceutical announced a strategic partnership and exclusive licensing agreement to develop and commercialize Tildacerfont for the treatment of congenital adrenal hyperplasia (CAH) in Japan. Under the terms of the agreement, Kaken will have the first right of negotiation to extend the agreement to include China (including Hong Kong, Taiwan, and Macau), South Korea, and other specified Southeast Asian (ASEAN) countries. Additionally, Kaken will be responsible for securing and maintaining the necessary regulatory approvals to market and sell Tildacerfont in Japan.

Also, in January 2021, Citrine Medicine announced a strategic partnership with Diurnal Group plc to bring Alkindi to China for the treatment of pediatric congenital adrenal hyperplasia (CAH). The partnership involves a licensing agreement, allowing Citrine Medicine to commercialize Alkindi(R) in the Chinese market. Alkindi is a medication used to manage CAH in children, specifically designed to provide more precise dosing compared to conventional treatments. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global congenital adrenal hyperplasia treatment market.

Competitive Landscape

The major global players in the congenital adrenal hyperplasia treatment market include Neurocrine Biosciences, Inc., Pfizer Inc., Johnson & Johnson Services, Inc., AdvaCare Pharma, Teva Pharmaceuticals USA, Inc., Sandoz, THE SEARLE COMPANY LTD., Spruce Biosciences, Inc., Crinetics Pharmaceuticals, Inc., BridgeBio Inc., and H. Lundbeck A/S among others.

Key Developments

• In January 2025, Crinetics Pharmaceuticals, Inc. reported positive topline results from a Phase 2 clinical trial evaluating atumelnant, an investigational drug for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome.
• In September 2024, BridgeBio Pharma, Inc. announced topline results from the Phase 1/2 ADventure study, an open-label trial evaluating BBP-631, the company's investigational adeno-associated virus (AAV) 5 gene therapy for the treatment of congenital adrenal hyperplasia (CAH).
• In May 2024, Spruce Biosciences will provide an update on the company's financial performance for the first quarter of 2024, along with key corporate and clinical developments. The analysis of data from the CAHmelia-203 study (a clinical trial evaluating tildacerfont in adults with congenital adrenal hyperplasia [CAH]) found that patients' response to tildacerfont correlated with their baseline glucocorticoid (GC) dose and drug compliance.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global congenital adrenal hyperplasia treatment market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug Type
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Investments in Research and Development
    • 4.1.1.2. Advancements in Treatment Options
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Treatment
    • 4.1.2.2. Limited Awareness and Diagnosis
  • 4.1.3. Opportunity
    • 4.1.3.1. Emerging Non-Steroidal Therapies
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
• 5.2. Emerging Pioneers and Prominent Players
• 5.3. Established leaders with largest selling Brand
• 5.4. Market leaders with established Product
• 5.5. CXO Perspectives
• 5.6. Latest Developments and Breakthroughs
• 5.7. Case Studies/Ongoing Research
• 5.8. Regulatory and Reimbursement Landscape
• 5.9. North America
• 5.10. Europe
• 5.11. Asia Pacific
• 5.12. Latin America
• 5.13. Middle East & Africa
• 5.14. Porter's Five Force Analysis
• 5.15. Supply Chain Analysis
• 5.16. Patent Analysis
• 5.17. SWOT Analysis
• 5.18. Unmet Needs and Gaps
• 5.19. Recommended Strategies for Market Entry and Expansion
• 5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.21. Pricing Analysis and Price Dynamics
• 5.22. Key Opinion Leaders

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Classic Congenital Adrenal Hyperplasia*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Nonclassic Congenital Adrenal Hyperplasia

7. By Drug Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 7.1.2. Market Attractiveness Index, By Drug Type
• 7.2. Corticosteroids*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Hydrocortisone
  • 7.2.4. Prednisone
  • 7.2.5. Dexamethasone
  • 7.2.6. Fludrocortisone
• 7.3. Crinecerfont
• 7.4. Spironolactone
• 7.5. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Injectable

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Neurocrine Biosciences, Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals, etc.
  • 12.1.5. SWOT Analysis
• 12.2. Pfizer Inc.
• 12.3. Johnson & Johnson Services, Inc.
• 12.4. AdvaCare Pharma
• 12.5. Teva Pharmaceuticals USA, Inc.
• 12.6. Sandoz
• 12.7. THE SEARLE COMPANY LTD.
• 12.8. Spruce Biosciences, Inc.
• 12.9. Crinetics Pharmaceuticals, Inc.
• 12.10. BridgeBio Inc.
• 12.11. H. Lundbeck A/S

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us